Published in Can J Neurol Sci on November 01, 1983
The short-term effect of an immunosuppressive treatment on CSF myelin basic protein in chronic progressive multiple sclerosis. J Neurol Neurosurg Psychiatry (1988) 0.79
Isolation of latent herpes simplex virus from the superior cervical and vagus ganglions of human beings. N Engl J Med (1978) 2.55
Monocyte activation and differentiation augment human endogenous retrovirus expression: implications for inflammatory brain diseases. Ann Neurol (2001) 2.16
Improved survival in patients with poor-prognosis malignant melanoma treated with adjuvant levamisole: a phase III study by the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol (1991) 2.06
The polypeptide and the DNA restriction enzyme profiles of spontaneous isolates of herpes simplex virus type 1 from explants of human trigeminal, superior cervical and vagus ganglia. J Gen Virol (1979) 1.86
Experimental allergic encephalomyelitis--properties of an iodinated encephalitogenic polypeptide. Immunochemistry (1967) 1.48
Isolation of Herpes simplex virus from human trigeminal ganglia, including ganglia from one patient with multiple sclerosis. Lancet (1977) 1.30
Variations in herpes simplex virus isolated from human ganglia and a study of clonal variation in HSV-1. Ann N Y Acad Sci (1980) 1.24
Recognition of the immunodominant myelin basic protein peptide by autoantibodies and HLA-DR2-restricted T cell clones from multiple sclerosis patients. Identity of key contact residues in the B-cell and T-cell epitopes. J Clin Invest (1997) 1.21
Radioimmunoassay with gel filtration for detecting antibody to basic proteins of myelin. J Lab Clin Med (1968) 1.18
Virus-specific intracytoplasmic inclusions in mouse brain produced by a newly isolated strain of Theiler virus. I. Virologic and morphologic studies. Lab Invest (1977) 1.18
Binding of encephalitogenic basic protein by serum alpha-globulins. Immunology (1970) 1.17
Use of a synthetic hapten in the demonstration of the Thomsen-Friedenreich (T) antigen on neuraminidase-treated human red blood cells and lymphocytes. J Immunol (1981) 1.13
Emotional stress and the development of multiple sclerosis: case-control evidence of a relationship. J Chronic Dis (1982) 1.13
Lymph node localization and whole body distribution of radioiodinated encephalitogenic polypeptide in guinea-pigs. Clin Exp Immunol (1968) 1.11
Anesthetic barbiturates in refractory status epilepticus. Can J Neurol Sci (1980) 1.09
A comparative analysis of restriction enzyme digests of the DNA of herpes simplex virus isolated from genital and facial lesions. J Gen Virol (1983) 1.08
Fine specificity of the antibody response to myelin basic protein in the central nervous system in multiple sclerosis: the minimal B-cell epitope and a model of its features. Proc Natl Acad Sci U S A (1995) 1.07
Detection of multiple strains of latent herpes simplex virus type 1 within individual human hosts. J Virol (1984) 1.04
Emotional stress and coping in multiple sclerosis (MS) exacerbations. J Psychosom Res (1991) 1.03
Detection by complementation of defective or uninducible (herpes simplex type 1) virus genomes latent in human ganglia. Proc Natl Acad Sci U S A (1979) 1.02
Attempts to transfer experimental allergic encephalomyelitis in guinea-pigs by lymph node fragments in millipore chambers. Clin Exp Immunol (1967) 0.99
Is encephalitogenic basic protein in human cerebrospinal fluid? Int Arch Allergy Appl Immunol (1970) 0.98
Association of neutrophil chemiluminescence with microbicidal activity. Clin Immunol Immunopathol (1982) 0.98
Contribution of incidence to increasing prevalence of multiple sclerosis in Alberta, Canada. Mult Scler (2008) 0.98
A double-blind controlled pilot study of plasma exchange versus sham apheresis in chronic progressive multiple sclerosis. Can J Neurol Sci (1985) 0.98
Pneumonitis with oral bcg. N Engl J Med (1977) 0.98
Relative frequency of autoantibodies to myelin basic protein and proteolipid protein in optic neuritis and multiple sclerosis cerebrospinal fluid. J Neurol Sci (1994) 0.98
Detection of antibodies to the basic protein of human myelin by radioimmunoassay and immunofluorescence. J Immunol (1971) 0.97
Effect of indomethacin on human neutrophil chemiluminescence and microbicidal activity. Immunopharmacology (1983) 0.97
Diminished adenosine A1 receptor expression on macrophages in brain and blood of patients with multiple sclerosis. Ann Neurol (2001) 0.96
Varicella-zoster virus infection of human brain cells and ganglion cells in tissue culture. Arch Virol (1978) 0.96
Anti-myelin basic protein and anti-proteolipid protein specific forms of multiple sclerosis. Ann Neurol (1994) 0.94
Responses of cancer patients in the MEM test: not just a function of charge on basic proteins. Br J Cancer (1976) 0.94
Radioimmunoassay of CSF for encephalitogenic basic protein: a diagnostic test for MS? Can Med Assoc J (1972) 0.94
Autoantibodies to myelin basic protein within multiple sclerosis central nervous system tissue. J Neurol Sci (1993) 0.92
Antigen-binding lymphocytes in normal man and guinea pig to human encephalitogenic protein. J Immunol (1973) 0.92
Increased synthetic peptide specificity of tissue-CSF bound anti-MBP in multiple sclerosis. J Neuroimmunol (1993) 0.91
Computer tomography in disseminated sclerosis. Can J Neurol Sci (1976) 0.89
Interferon production by lymphocytes from multiple sclerosis and non-MS patients. Neurology (1983) 0.89
Tolerance induction to myelin basic protein by intravenous synthetic peptides containing epitope P85 VVHFFKNIVTP96 in chronic progressive multiple sclerosis. J Neurol Sci (1997) 0.89
Evidence for cardiovascular autonomic nerve dysfunction in multiple sclerosis. J Neurol Neurosurg Psychiatry (1984) 0.89
Automated sample application for gel filtration. Anal Biochem (1969) 0.88
Properties of antibodies produced in rabbits to human myelin and myelin basic protein. Int Arch Allergy Appl Immunol (1972) 0.88
Experimental allergic encephalomyelitis: immunological properties of encephalitogenic polypeptides and proteins. Clin Exp Immunol (1967) 0.88
Tissue culture of adult human neurons. Neurosci Lett (1979) 0.88
Purification of autoantibodies to myelin basic protein by antigen specific affinity chromatography from cerebrospinal fluid IgG of multiple sclerosis patients. Immunoreactivity studies with human myelin basic protein. J Neurol Sci (1991) 0.87
Neuronal and lymphocytic populations in human trigeminal ganglia: implications for ageing and for latent virus. Neuropathol Appl Neurobiol (1982) 0.87
Diagnostic value of cerebrospinal fluid anti-myelin basic protein in patients with multiple sclerosis. Ann Neurol (1986) 0.86
A correlation between cerebrospinal fluid myelin basic protein and anti-myelin basic protein in multiple sclerosis patients. Ann Neurol (1987) 0.85
Synthetic peptide specificity of anti-myelin basic protein from multiple sclerosis cerebrospinal fluid. J Neuroimmunol (1992) 0.85
Virology and histopathology of the trigeminal ganglia of Americans and Japanese. Can J Neurol Sci (1978) 0.85
Prevalence, incidence, and characteristics of multiple sclerosis in Westlock County, Alberta, Canada. Neurology (1993) 0.85
A computer project in clinical immunology. Med J Aust (1967) 0.85
Adjuvant chemoimmunotherapy after regional lymphadenectomy for malignant melanoma. Am J Clin Oncol (1987) 0.84
Recovery of herpes simplex virus genetic information from human trigeminal ganglion cells following superinfection with herpes simplex virus type 2 temperature-sensitive mutants. J Gen Virol (1984) 0.84
Carcinoembryonic antigen levels as an indicator of the primary site in metastatic disease of unknown origin. Cancer (1981) 0.83
Effect of sex and reproductive history on the survival of patients with colorectal cancer. J Chronic Dis (1982) 0.83
Radioiodinated peanut lectin: clinical use as a tumour-imaging agent and potential use in assessing renal-tubular function. Eur J Nucl Med (1986) 0.83
Recovery of latent herpes simplex virus from human trigeminal nerve roots. Arch Virol (1982) 0.82
Variable restriction endonuclease sites of herpes simplex virus type 1 isolates from encephalitic, facial and genital lesions and ganglia. J Gen Virol (1983) 0.82
Decreased levels of circulating lytic anti-T in the serum of patients with metastatic gastrointestinal cancer: a correlation with disease burden. Clin Exp Immunol (1982) 0.82
Surgery as an alternative to chemotherapy for hepatic metastases from colorectal cancer. Can J Surg (1983) 0.82
Components in multiple sclerosis cerebrospinal fluid that are detected by radioimmunoassay for myelin basic protein. Proc Natl Acad Sci U S A (1978) 0.82
Kinetic profiles of cerebrospinal fluid anti-MBP in response to intravenous MBP synthetic peptide DENP(85)VVHFFKNIVTP(96)RT in multiple sclerosis patients. Mult Scler (2000) 0.81
Gallium-67 scintigraphy in multisystem malignant melanoma. Radiology (1977) 0.81
Multiple sclerosis and associated diseases: a relationship to diabetes mellitus. Can J Neurol Sci (1981) 0.81
Intrathecal synthesis of autoantibodies to myelin basic protein in multiple sclerosis. Can J Neurol Sci (1986) 0.81
Factors affecting recovery of latent herpes simplex virus from human trigeminal ganglia. Can J Microbiol (1982) 0.81
Experimental autoimmune encephalomyelitis. Digestion of basic protein of human myelin with cyanogen bromide and trypsin. Immunology (1970) 0.81
How multiple sclerosis is related to animal illness, stress and diabetes. Can Med Assoc J (1982) 0.80
The relationship between levels of cerebrospinal fluid myelin basic protein and IgG measurements in patients with multiple sclerosis. Ann Neurol (1985) 0.80
Purification of fully active human encephalitogenic basic protein on sulfoethyl-sephadex. Can J Biochem (1972) 0.80
A double antibody radioimmunoassay for myelin basic protein in cerebrospinal fluid. Clin Biochem (1985) 0.80
Retinol and postoperative colorectal cancer patients. Br J Cancer (1985) 0.79
Humoral and cellular immunity to paternal antigens in trophoblastic neoplasia. Int J Cancer (1979) 0.79
Effect of methylprednisolone on CSF IgG parameters, myelin basic protein and anti-myelin basic protein in multiple sclerosis exacerbations. Can J Neurol Sci (1986) 0.79
Acute demyelinating disease in a chimpanzee three years after inoculation of brain cells from a patient with MS. Ann Neurol (1979) 0.79
Pulmonary manifestations in patients with malignant melanoma during BCG immunotherapy. A preliminary report. Chest (1979) 0.79
Geographic and temporal distribution of mortality rates for multiple sclerosis in Canada, 1965-1994. Neuroepidemiology (2003) 0.78
Circulating immune complexes in multiple sclerosis: relation with disease activity. Neurology (1982) 0.78
Cerebrospinal fluid myelin basic protein as a prognostic marker in patients with head injury. Crit Care Med (1985) 0.78
HLA-D typing with an association of Dw2 and absent immune responses towards herpes simplex (type i) antigen in multiple sclerosis. Transplant Proc (1977) 0.78
Can a defective herpes simplex virus cause multiple sclerosis? Perspect Biol Med (1978) 0.78
Phase I pharmacotoxicology study of human fibroblast interferon in human cancers. J Natl Cancer Inst (1980) 0.78
Optic neuritis anti-myelin basic protein synthetic peptide specificity. J Neurol Sci (1992) 0.78
Cutaneous malignant melanoma in Alberta: 1967-1976. Cancer (1983) 0.78
Prevalence of multiple sclerosis in Barrhead County, Alberta, Canada. Can J Neurol Sci (1992) 0.77
Carcinoembryonic antigen: usefulness as a postsurgical method in the detection of recurrence in Dukes stages B2 and C colorectal cancers. J Natl Cancer Inst (1982) 0.77
Natural human interferon-beta in metastatic malignant melanoma. A phase II study. Acta Oncol (1988) 0.77
Myelin basic protein: a component of circulating immune complexes in multiple sclerosis. Can J Neurol Sci (1983) 0.76
Risk factors by onset age in multiple sclerosis. Neuroepidemiology (1991) 0.76
Adjuvant BCG immunotherapy for malignant melanoma. Can Med Assoc J (1984) 0.76